Tem Group has been acquired by Instrumentation Laboratory
The shareholders of Tem Group (TEM) have sold the company to Instrumentation Laboratory (IL). Financial details have not been disclosed.
TEM is a global leader in in-vitro diagnostic (IVD) testing for Patient Blood Management (PBM) with their flagship ROTEM testing systems. With a direct sales force in seven markets, including the USA, TEM has consistently achieved above market growth in the PBM market. In hospital trauma and surgical patients with clinically significant bleeding, ROTEM whole blood analyzers provide a rapid differential diagnosis of coagulopathies. This supports targeted transfusion and coagulation factor concentrate therapy and, as a result, is key to PBM programs. PBM is a multi-disciplinary, evidence-based medical concept, optimizing a patient’s own blood volume, minimizing blood loss and thereby significantly reducing or avoiding blood transfusion.
IL, founded in 1959 and based in Bedford, Massachusetts, is a worldwide developer, manufacturer and distributor of in-vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company’s product lines include critical care systems, hemostasis systems and information management systems. IL is an integral part of the Werfen family of companies which distributes its products by a direct sales force in North America and Werfen organizations around the globe.
"A passion for innovation, leading systems and extensive knowledge in PBM, make TEM a perfect complement to our focus, commitment, and leadership in hemostasis and critical care IVD," said Ramon Benet, CEO at IL. "IL and our global Werfen organizations are ideally positioned to maximize the potential of the ROTEM product line, which intersects our existing business and presents synergies in our core competencies and customer call points. Most importantly, ROTEM systems share the same ultimate benefit of all our products, to help customers reduce overall hospital costs, while improving patient care."
Oaklins' team in Switzerland advised the seller in this transaction.
Talk to the deal team
Related deals
HD Clinical Ltd. has been acquired by NEXUS AG
NEXUS AG has acquired HD Clinical Ltd. Through this acquisition, NEXUS has gained a recognized and internationally active team of experts in structured diagnostic reporting and image processing. This will provide new regional access, strengthening its strong European market position in software, particularly for internal medicine.
Learn moreReed Veterinary Surgery has been acquired by Kin Vet Community
The acquisition of Reed Veterinary Surgery by Kin Vet Community has been successfully completed. Through this acquisition, the surgery joins a community of veterinary clinics where colleagues share knowledge and best practices to improve the wellbeing of their clients and their animals.
Learn morePanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
Learn more